<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="144"><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="28529"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/IIa, safety and efficacy study of AFTVac in hepatocellular carcinoma patients</ProtocolTitle><Sponsor>Cell-Medicine Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="37218"></Trial><Drug id="55115">AFTVac</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 Combined With Nivolumab versus Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, bristol myers squibb international corporation belgium</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="350572"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="360513"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-09</ProtocolAcronym><ProtocolTitle>A phase III clinical study to assess the effect of bempegaldesleukin in combination with nivolumab compared to tyrosine kinase inhibitor (TKI) monotherapy in patients with advanced metastatic renal cell carcinoma</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="372111"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study in Patients With HPV+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</ProtocolTitle><Sponsor>Cue Biopharma Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="383734"></Trial><Drug id="105120">CUE-101</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study in Patients With HPV+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</ProtocolTitle><Sponsor>Cue Biopharma Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="383734"></Trial><Drug id="105120">CUE-101</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="755">Lung tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28011"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-521873 in Advanced Solid Tumors, MTD Finding</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62646"></Trial><Drug id="57922">NHS-IL2-LT</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>IT-MATTERS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Leukocyte Interleukin, Injection (LI) to Treat Cancer of the Oral Cavity</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="73333"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 Combined With Nivolumab versus Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, bristol myers squibb international corporation belgium</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3256">Stage III melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="350572"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical efficacy study of immunotherapy with Multikine in treatment-naive prostate cancer patients</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="41721"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II safety, tolerability, pharmacokinetics, and efficacy study of an IL-2 antagonist BAY-50-4798, in HIV patients</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="9220"></Trial><Drug id="28450">AIC-284</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2446">Leiomyosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>IT-MATTERS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Leukocyte Interleukin, Injection (LI) to Treat Cancer of the Oral Cavity</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="73333"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="740">Uterus tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multi-center, safety and efficacy study of neoadjuvant immunotherapy with Multikine, in patients with squamous cell carcinoma of the head and neck</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="41761"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, safety and efficacy study of Multikine in patients with head and neck cancer</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="41758"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II, open-label, randomized, dose-ranging study to assess optimum dose, safety,and efficacy of Multikine in head and neck cancer patients</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="41757"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety, tolerability and efficacy study of Multikine in patients with squamous cell head and neck cancer</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="41749"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAIL</ProtocolAcronym><ProtocolTitle>Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="87716"></Trial><Drug id="45937">autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIb, randomized, safety and efficacy study of AFTVac in patients with hepatocellular carcinoma</ProtocolTitle><Sponsor>Cell-Medicine Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="37159"></Trial><Drug id="55115">AFTVac</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, pilot study to evaluate safety, feasibility and clinical response of AFTVac in glioblastoma multiforme patients</ProtocolTitle><Sponsor>Cell-Medicine Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="37075"></Trial><Drug id="55115">AFTVac</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma</ProtocolTitle><Sponsor>Altor BioScience Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="62586"></Trial><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2446">Leiomyosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer</ProtocolTitle><Sponsor>Altor BioScience Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2380">Bladder cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="88603"></Trial><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="28529"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of BAY-50-4798 in Patients With HIV Infection</ProtocolTitle><Sponsor>Bayer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="13695"></Trial><Drug id="28450">AIC-284</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="194">Sarcoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PORTER</ProtocolAcronym><ProtocolTitle>Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations</ProtocolTitle><Sponsor>Parker Institute for Cancer Immunotherapy</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="369648"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III registrational trial of NKTR-214 in first-line advanced melanoma patients</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="349635"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I clinical trial to evaluate safety of TILT-123 in patients with metastatic melanoma</ProtocolTitle><Sponsor>TILT Biotherapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="341809"></Trial><Drug id="92317">TILT-123</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread</ProtocolTitle><Sponsor>Masonic Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="74920"></Trial><Drug id="70160">salmonella-IL-2 cancer therapy (oral, cancer), Botanic Oil Innovations</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I clinical trial to evaluate the safety and efficacy of BAY-50-4798 in the treatment of patients with advanced renal cell carcinoma or melanoma</ProtocolTitle><Sponsor>City of Hope Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="286299"></Trial><Drug id="28450">AIC-284</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2447">Liposarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2444">Chondrosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2718">Histiocytoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, clinical study of SO-C101 in patients with both solid tumors and hematological malignancies</ProtocolTitle><Sponsor>Sotio AS</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="2054">Hematological neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="352032"></Trial><Drug id="74941">SO-C101</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I clinical trial to evaluate the safety and efficacy of BAY-50-4798 in the treatment of patients with advanced renal cell carcinoma or melanoma</ProtocolTitle><Sponsor>City of Hope Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="286299"></Trial><Drug id="28450">AIC-284</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multi-center, clinico-pathological efficacy study of neo-adjuvant Multikine immunotherapy, in patients with oral squamous cell carcinoma (OSCC)</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="41890"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II, multi-center, clinico-pathological study of Multikine in patients with advanced primary oral squamous cell carcinoma</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="41872"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="28529"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/IIa, prospective clinical trial to evaluate the safety and efficacy of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma multiforme</ProtocolTitle><Sponsor>Cell-Medicine Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="80200"></Trial><Drug id="55115">AFTVac</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ALT-801-Activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia</ProtocolTitle><Sponsor>Altor BioScience Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="82721"></Trial><Drug id="63685">ALT-801 (donor lymphocyte infusion, cancer), Altor</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pilot study to evaluate the effects of VB10.NEO in combination with NKTR-214 in patients with squamous cell carcinoma of the head and neck</ProtocolTitle><Sponsor>Vaccibody AS</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="354207"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROPEL</ProtocolAcronym><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3466">Metastatic bladder cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="296922"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)</ProtocolTitle><Sponsor>Nektar Therapeutics, PPD Development (S) Pte Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="358884"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A first-in-human, phase I/Ib study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in selected patients with advanced/metastatic solid tumors</ProtocolTitle><Sponsor>Sotio AS</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="352089"></Trial><Drug id="74941">SO-C101</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28011"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2380">Bladder cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28011"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I clinical trial to evaluate the safety and efficacy of BAY-50-4798 in the treatment of patients with advanced renal cell carcinoma or melanoma</ProtocolTitle><Sponsor>City of Hope Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="286299"></Trial><Drug id="28450">AIC-284</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3668">Metastatic lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical efficacy study of Multikine in patients with breast cancer</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="41707"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study of Multikine to evaluate its safety and to determine its effect on various immune system responses</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="9465"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PAW</ProtocolAcronym><ProtocolTitle>Study of Leukocyte Interleukin Injection for Treatment of Perianal Warts</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1232">Condyloma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="286956"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Determine if Either of Two Doses of Study Drug Given With a Low-Dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-Based Second-Line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression</ProtocolTitle><Sponsor>EMD Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="35819"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="28529"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multicenter, randomized, open-label, parallel-group study to assess the safety and efficacy of EMD-273066 following low-dose cyclophosphamide compared to supportive care alone in patients with small cell lung cancer</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="89159"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical study to evaluate the safety and efficacy of the triple combination of BXCL-701, NKTR-214 and avelumab for the treatment of patients with pancreatic cancer</ProtocolTitle><Sponsor>BioXcel Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="372194"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase Ib/II clinical trial to evaluate the anti-cancer activity of the combined agents, avelumab, talazoparib and NKTR-214 and separately avelumab, enzalutamide and NKTR-214 in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="359129"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3235">Merkel cell carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3466">Metastatic bladder cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase III, safety and efficacy study of interleukin-2 follow-on-biologic, Zenotech in patients with renal cell carcinoma</ProtocolTitle><Sponsor>Zenotech Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="271068"></Trial><Drug id="79967">interleukin-2 follow-on-biologic, Zenotech</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-2</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS-4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="372173"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I trial to evaluate TILT-123 in combination with PD-1 or PD-L1 blockade therapy in CPI-refractory solid tumors</ProtocolTitle><Sponsor>TILT Biotherapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="375764"></Trial><Drug id="92317">TILT-123</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="54">Carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28529"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-10</ProtocolAcronym><ProtocolTitle>A Randomized Study of NKTR-214 Plus Nivolumab and of Reference Chemotherapy in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer With Low PD-L1 Expression</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="364590"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-10</ProtocolAcronym><ProtocolTitle>A Randomized Study of NKTR-214 Plus Nivolumab and of Reference Chemotherapy in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer With Low PD-L1 Expression</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="364590"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-521873 in Advanced Solid Tumors, MTD Finding</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62646"></Trial><Drug id="57922">NHS-IL2-LT</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1772">Osteosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multi-center, safety and efficacy study of neoadjuvant immunotherapy with Multikine, in patients with squamous cell carcinoma of the head and neck</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="41761"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pilot study to evaluate the effects of VB10.NEO in combination with NKTR-214 in patients with squamous cell carcinoma of the head and neck</ProtocolTitle><Sponsor>Vaccibody AS</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="354207"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical safety, feasibility and efficacy study of Multikine in patients with prostate cancer</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="41716"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="194">Sarcoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="194">Sarcoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROPEL</ProtocolAcronym><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="296922"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3466">Metastatic bladder cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A trial to evaluate TILT-123 in combination with CAR T-cell therapy for solid tumors</ProtocolTitle><Sponsor>TILT Biotherapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="375774"></Trial><Drug id="92317">TILT-123</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROPEL</ProtocolAcronym><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="296922"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I safety, pharmacokinetics, and biological pharmacodynamics study of EMD-273066 in patients with prostate cancer</ProtocolTitle><Sponsor>EMD Lexigen Research Center Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="37162"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-521873 Plus Radiotherapy in Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51498"></Trial><Drug id="57922">NHS-IL2-LT</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II, multi-center, clinico-pathological study of Multikine in patients with advanced primary oral squamous cell carcinoma</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="41872"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2443">Angiosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A case study of bone-metastatic breast cancer with autologous formalin-fixed tumor vaccine</ProtocolTitle><Sponsor>Innoshima-Ishikai Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130015"></Trial><Drug id="55115">AFTVac</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treating High Risk Leukemia With CD40 Ligand and IL-2 Gene Modified Tumor Vaccine</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184129"></Trial><Drug id="45937">autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, clinical study of SO-C101 in patients with both solid tumors and hematological malignancies</ProtocolTitle><Sponsor>Sotio AS</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="352032"></Trial><Drug id="74941">SO-C101</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase Ib/II clinical trial to evaluate the anti-cancer activity of the combined agents, avelumab, talazoparib and NKTR-214 and separately avelumab, enzalutamide and NKTR-214 in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="359129"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety and efficacy study of Multikine in patients with head and neck cancer</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="41756"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of Multikine in the Treatment of Perianal Warts</ProtocolTitle><Sponsor>United States Naval Medical Center, San Diego</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1232">Condyloma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="182223"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalating safety study of immunotherapy with the leukocyte interleukin injection Multikine for the treatment of human papilloma virus (HPV) induced cervical dysplasia, in HIV patients</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1235">Cervical dysplasia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="41727"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/IIa study to evaluate the safety and efficacy of AFTVac in patients with newly diagnosed glioblastoma multiforme</ProtocolTitle><Sponsor>Tokyo Women's Medical College</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="67525"></Trial><Drug id="55115">AFTVac</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase Ib/II clinical trial to evaluate the anti-cancer activity of the combined agents, avelumab, talazoparib and NKTR-214 and separately avelumab, enzalutamide and NKTR-214 in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="359129"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase Ib/II trial to evaluate the safety and efficacy of NKTR-214 in combination with entinostat, in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 (programmed death receptor-1) agent</ProtocolTitle><Sponsor>Syndax Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="341373"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROPEL</ProtocolAcronym><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="296922"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="54">Carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28011"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="194">Sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multi-center, clinico-pathological efficacy study of neo-adjuvant Multikine immunotherapy, in patients with oral squamous cell carcinoma (OSCC)</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="41890"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety, tolerability and efficacy study of Multikine in patients with squamous cell head and neck cancer</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="41749"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treating High Risk Leukemia With CD40 Ligand and IL-2 Gene Modified Tumor Vaccine</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184129"></Trial><Drug id="45937">autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>MSB-0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma</ProtocolTitle><Sponsor>EMD Serono Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="159844"></Trial><Drug id="57922">NHS-IL2-LT</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>